| Compound | Vilon |
|---|---|
| Category | Khavinson immune bioregulator dipeptide |
| Class | Other Injectables |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
Vilon is catalogued here as a khavinson immune bioregulator dipeptide and graded at the "Minimal evidence" evidence tier. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A dipeptide (Lys-Glu) from the bioregulation program studied for immune and chromatin effects.
Mechanism of Action
Proposed immunoregulatory and gene-activation effects within the bioregulation theory.
Research and Evidence
Regional literature, including some small registered-product studies.
Safety and Side Effects
Sparse data.
Frequently Asked Questions
What is the evidence tier of Vilon?
Vilon is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is Vilon an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for Vilon?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — search for Vilon peptide studies. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.